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The coronavirus disease (COVID-19) pandemic has affected clinical management of tubercu-
losis (TB) and TB-related services (1,2). Reports of 
the first cohorts of patients with COVID-19 and TB 
have been recently published (3,4), although it may 
be difficult to distinguish which infection occurred 
first (5). The effects of COVID-19 on TB diagnostic 
and programmatic activities are similar (1). Almost 
every country has national TB programs in place, 
whereas national programs for COVID-19 are ur-
gently needed (1,2).
The effect of COVID-19 on TB services is esti-
mated to be dramatic, especially in countries where 
healthcare staff involved in TB management have 
been reassigned to the COVID-19 emergency. How-
ever, apart from local studies (6), a comprehensive, 
multinational description is needed.
The Global Tuberculosis Network, which con-
ducted this study, collaborates with TB centers from 
41 countries (3,4,6,7). We studied patient attendance 
at TB centers in 16 countries and compared the vol-
ume of TB-related healthcare activities in the first 4 
months of the COVID-19 pandemic, January–April 
2020, with that for the same period in 2019.
The Study
We invited 37 TB centers to participate in the study 
and collected data from 33 centers located in 16 coun-
tries on 5 continents (Appendix Tables 1, 2, https://
wwwnc.cdc.gov/EID/article/26/11/20-3163-App1.
pdf). The participating centers received ethics clear-
ance according to their respective center regulations 
(7,8). Active TB disease and latent TB infection (LTBI) 
were defined according to international guidelines 
(9,10). We recorded numbers of patients with active 
TB discharged from inpatient care, patients with new-
ly diagnosed cases of active TB, patients with active TB 
visiting outpatient settings, and new and total outpa-
tient visits for LTBI. We defined use of telehealth ser-
vices as implementation of directly observed therapy 
during face-to-face virtual teleconsultations, which 
were considered to be equivalent to outpatient visits 
and were counted as such. We did not consider pa-
tient contact by telephone and emails to be telehealth. 
Home visits were considered outpatient visits. We 
also recorded national lockdown dates. If a country 
reported results from >1 center, we used the sum of 
the attendances to generate the graphs. Quantitative 
variables were summarized with absolute (percent-
age) frequencies.
Of the 16 countries studied, data were contributed 
by 4 TB centers each in Italy, Russia, Spain, and Brazil; 3 
each in Sierra Leone and Niger; 2 in Mexico; and 1 each 
in 9 other countries (Appendix Tables 1, 2). Lockdowns 
were imposed in all countries (Appendix Figures 1, 2). 
The earliest lockdown start date was February 1, 2020 
(Australia); the latest was April 7, 2020 (Singapore). 
By the end of data collection (April 30), none of the 16 
countries had reduced lockdown severity.
Data on new active TB cases were available from 
32 of the 33 TB centers. Except for 5 centers (Sydney, 
New South Wales, Australia; San Fernando, the Philip-
pines; Turin, Italy; Asturias, Spain; and London, UK), 
which each reported stable numbers or moderate in-
creases, new active TB cases decreased in 27 (84%) of 
the 32 TB centers in the first 4 months of 2020 relative 
to the same period in 2019 (Appendix Figure 1).
Information about total outpatient TB visits was 
available for 29 centers but not from Groningen, the 
Netherlands; Mexico City, Mexico; Porto Alegre, Bra-
zil, and Nairobi, Kenya. A total of 22 (75%) of 29 TB 
centers from 14 countries registered decreased outpa-
tient visits during the lockdowns.
Active TB–associated hospital discharges differed 
in 2020 from 2019. Although data were not available 
for a few centers (Buenos Aires, Argentina; Nairobi; 
and the 3 centers in Niger), data for San Fernando, 
Singapore; Mexico City, Groningen, and London 
indicated minimal or no increase. Active TB–associ-
ated hospital discharges for the remaining 23 (82%) 
of 28 TB centers were lower during the first 4 months 
of 2020.
Data for LTBI outpatient visits were available 
from 16 of the 33 TB centers; 13 (81%) recorded de-
creased total outpatient visits (all except Hastings, 
Sierra Leone; Alvorada, Brazil; and Barcelona, Spain) 
(Appendix Figure 2). Data for newly diagnosed LT-
BIs were available from 19 of the 33 TB centers. New 
LTBI outpatient visits at 18 (95%) of 19 TB centers (all 
except Alvorada) were fewer during the lockdown 
period (Appendix Figure 2).
During the first 4 months of 2020, telehealth ser-
vices were used by 7 (21%) of the 33 TB centers. The 
number of patients using telehealth services was re-
ported by 4 centers: Sydney; Mumbai, India; London; 
and Arkhangelsk, Russia. Increased use of telehealth 
services correlated with lockdown implementation; 
most uses were recorded in April 2020 (Appendix 
Tables 1, 2).
Coronavirus disease has disrupted tuberculosis services 
globally. Data from 33 centers in 16 countries on 5 conti-
nents showed that attendance at tuberculosis centers was 
lower during the first 4 months of the pandemic in 2020 
than for the same period in 2019. Resources are needed 
to ensure tuberculosis care continuity during the pandemic.
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Conclusions 
For most TB centers during their respective national 
lockdowns in the first 4 months of 2020, we found re-
ductions in TB-related hospital discharges, newly diag-
nosed cases of active TB, total active TB outpatient visits, 
and new LTBI and LTBI outpatient visits. These results 
may be explained by a general decrease in the use of 
health services, including emergency services (11). Re-
sources for TB service provision were reassigned to 
other medical services. Outpatient visit numbers may 
have decreased because of patients’ fear of exposure to 
severe acute respiratory syndrome coronavirus 2 (12). 
Access to medical services may have decreased because 
of interruptions in or difficulty accessing public trans-
portation, although health-related travel was permitted 
in most countries. In some TB centers (e.g., Mexico City), 
the hospital patient intake system was modified to sup-
port COVID-19 admissions, thus severely hindering TB 
services. In some centers, screening for LTBI was con-
sidered a lower priority than screening for active TB or 
COVID-19. Because of lockdowns, reactivation of active 
TB in persons with LTBI who did not receive preventive 
therapy may be expected, such as in contacts recently 
exposed to TB or in those who are immunocompro-
mised (13,14). In England, compared with 2019, TB noti-
fications decreased by 16.5% during April and by 37.3% 
during May 2020; the LTBI program was paused in re-
sponse to COVID-19 on March 26 (15).
Lockdowns have favored the increased use of 
telemedicine. Telehealth is a new service offered by 
TB programs. In TB centers surveyed in Australia, 
Russia, India, and the United Kingdom, telehealth 
service use increased in the first 4 months of 2020. 
Although our study cannot comprehensively de-
scribe all features of TB management, we found that 
the COVID-19 pandemic had a substantial impact 
on TB services worldwide. The main strength of our 
study is the global coverage from 33 TB centers from 
16 countries on 5 continents. Limitations include lack 
of data from some countries. In 9 of the 16 countries, 
data were limited to reports from only 1 TB center, 
which may not have fully represented that nation’s 
TB healthcare activities. In addition, some TB centers 
were located in countries with low TB incidence (e.g., 
Italy). The description of the changes in the TB bur-
den over a few months did not allow for appropriate 
statistical inferences in these countries with low TB 
incidence. More information about the medium- and 
long-term effects of the COVID-19 pandemic on TB 
services after a specified time from the diagnosis of 
the first COVID-19 patient in each country is needed.
The COVID-19 pandemic seems to have affected 
TB services in all 16 countries that provided data. 
At select TB centers, increased use of telehealth 
services during the pandemic was recorded. Re-
sources urgently need to be channeled to ensure that 
TB care continues efficiently despite the ongoing 
COVID-19 pandemic.
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World TB Day, falling on March 24th each year, is designed 
to build public awareness that tuberculosis today remains an 
epidemic in much of the world, causing the deaths of nearly 
one-and-a-half million people each year, mostly in developing 
countries. It commemorates the day in 1882 when Dr Robert 
Koch astounded the scientific community by announcing that 
he had discovered the cause of tuberculosis, the TB bacillus. 
At the time of Koch’s announcement in Berlin, TB was raging 
through Europe and the Americas, causing the death of one 
out of every seven people. Koch’s discovery opened the way 
towards diagnosing and curing TB.
Click on the link below to access Emerging Infectious 
Diseases articles and podcasts, and to learn more about 
the latest information and emerging trends in TB.
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